Journal
BLOOD
Volume 120, Issue 4, Pages 709-719Publisher
AMER SOC HEMATOLOGY
DOI: 10.1182/blood-2012-01-403212
Keywords
-
Categories
Funding
- Scholar award from the Leukemia & Lymphoma Society (White Plains, NY)
- CancerFreeKids Association
- National Institutes of Health (NIH) grant [CA118319]
- Institutional Clinical and Translational Science Award, NIH/NCRR Grant [1UL1RR026314-01]
Ask authors/readers for more resources
AML1-ETO (AE) is a fusion product of translocation (8;21) that accounts for 40% of M2 type acute myeloid leukemia (AML). In addition to its role in promoting preleukemic hematopoietic cell self-renewal, AE represses DNA repair genes, which leads to DNA damage and increased mutation frequency. Although this latter function may promote leukemogenesis, concurrent p53 activation also leads to an increased baseline apoptotic rate. It is unclear how AE expression is able to counterbalance this intrinsic apoptotic conditioning by p53 to promote survival and self-renewal. In this report, we show that Bcl-xL is up-regulated in AE cells and plays an essential role in their survival and self-renewal. Further investigation revealed that Bcl-xL expression is regulated by thrombopoietin (THPO)/MPL-signaling induced by AE expression. THPO/MPL-signaling also controls cell cycle reentry and mediates AE-induced self-renewal. Analysis of primary AML patient samples revealed a correlation between MPL and Bcl-xL expression specifically in t(8;21) blasts. Taken together, we propose that survival signaling through Bcl-xL is a critical and intrinsic component of a broader self-renewal signaling pathway downstream of AML1-ETO-induced MPL. (Blood. 2012;120(4):709-719)
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available